Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013 (2013), Article ID 981984, 10 pages
http://dx.doi.org/10.1155/2013/981984
Research Article

Differential Expression of Host Biomarkers in Saliva and Serum Samples from Individuals with Suspected Pulmonary Tuberculosis

DST/NRF Centre of Excellence for Biomedical Tuberculosis Research and MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Stellenbosch, P.O. Box 19063, Francie van Zijl Drive, Tygerberg 7505, South Africa

Received 4 August 2013; Accepted 18 September 2013

Academic Editor: Yves Denizot

Copyright © 2013 Khutso G. Phalane et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organisation, “Global tuberculosis report 2012,” Tech. Rep., 2012. View at Google Scholar
  2. C. J. L. Murray, E. DeJonghe, H. J. Chum, D. S. Nyangulu, A. Salomao, and K. Styblo, “Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries,” The Lancet, vol. 338, no. 8778, pp. 1305–1308, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Apers, J. Mutsvangwa, J. Magwenzi et al., “A comparison of direct microscopy, the concentration method and the Mycobacteria Growth Indicator Tube for the examination of sputum for acid-fast bacilli,” International Journal of Tuberculosis and Lung Disease, vol. 7, no. 4, pp. 376–381, 2003. View at Google Scholar · View at Scopus
  4. N. N. Chegou, K. G. Hoek, M. Kriel, R. M. Warren, T. C. Victor, and G. Walzl, “Tuberculosis assays: past, present and future,” Expert Review of Anti-Infective Therapy, vol. 9, no. 4, pp. 457–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. B. A. Hanna, A. Ebrahimzadeh, L. B. Elliott et al., “Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria,” Journal of Clinical Microbiology, vol. 37, no. 3, pp. 748–752, 1999. View at Google Scholar · View at Scopus
  6. C. C. Boehme, P. Nabeta, D. Hillemann et al., “Rapid molecular detection of tuberculosis and rifampin resistance,” The New England Journal of Medicine, vol. 363, no. 11, pp. 1005–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. R. Steingart, H. Sohn, I. Schiller et al., “Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD009593, 2013. View at Google Scholar
  8. A. Trébucq, D. A. Enarson, C. Y. Chiang et al., “Xpert MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?” International Journal of Tuberculosis and Lung Disease, vol. 15, no. 12, pp. 1567–1572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. B. J. Marais and M. Pai, “New approaches and emerging technologies in the diagnosis of childhood tuberculosis,” Paediatric Respiratory Reviews, vol. 8, no. 2, pp. 124–133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. N. N. Chegou, G. Walzl, C. T. Bolliger, A. H. Diacon, and M. M. van den Heuvel, “Evaluation of adapted whole-blood interferon-γ release assays for the diagnosis of pleural tuberculosis,” Respiration, vol. 76, no. 2, pp. 131–138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Munk, S. M. Arend, I. Brock, T. H. M. Ottenhoff, and P. Andersen, “Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis,” Journal of Infectious Diseases, vol. 183, no. 1, pp. 175–176, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. Schipper, E. Silletti, and M. H. Vingerhoeds, “Saliva as research material: biochemical, physicochemical and practical aspects,” Archives of Oral Biology, vol. 52, no. 12, pp. 1114–1135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Gustafsson, V. Ajeti, and L. Ljunggren, “Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels,” Biomarker Insights, vol. 6, pp. 119–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Pant Pai, R. Joshi, S. Dogra et al., “Evaluation of diagnostic accuracy, feasibility and client preference for rapid oral fluid-based diagnosis of HIV infection in rural India,” PLoS ONE, vol. 2, no. 4, article e367, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Boehme, E. Molokova, F. Minja et al., “Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 99, no. 12, pp. 893–900, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. S. F. Kingsmore, “Multiplexed protein measurement: technologies and applications of protein and antibody arrays,” Nature Reviews Drug Discovery, vol. 5, no. 4, pp. 310–320, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. L. Luque-Garcia and T. A. Neubert, “Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry,” Journal of Chromatography A, vol. 1153, no. 1-2, pp. 259–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Mutetwa, C. Boehme, M. Dimairo et al., “Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients,” International Journal of Tuberculosis and Lung Disease, vol. 13, no. 10, pp. 1253–1259, 2009. View at Google Scholar · View at Scopus
  19. A. Thakur, L. E. Pedersen, and G. Jungersen, “Immune markers and correlates of protection for vaccine induced immune responses,” Vaccine, vol. 30, pp. 4907–4920, 2012. View at Google Scholar
  20. R. S. Wallis, P. Kim, S. Cole et al., “Tuberculosis biomarkers discovery: developments, needs, and challenges,” The Lancet Infectious Diseases, vol. 13, pp. 362–372, 2013. View at Google Scholar
  21. G. Walzl, K. Ronacher, W. Hanekom, T. J. Scriba, and A. Zumla, “Immunological biomarkers of tuberculosis,” Nature Reviews Immunology, vol. 11, no. 5, pp. 343–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. T. R. Malek, “The biology of interleukin-2,” Annual Review of Immunology, vol. 26, pp. 453–479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Biselli, S. Mariotti, V. Sargentini et al., “Detection of interleukin-2 in addition to interferon-γ discriminates active tuberculosis patients, latently infected individuals, and controls,” Clinical Microbiology and Infection, vol. 16, no. 8, pp. 1282–1284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Wang, N. Diao, C. Lu et al., “Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population,” PLoS ONE, vol. 7, Article ID e51338, 2012. View at Google Scholar
  25. T. Kishimoto, “IL-6: from its discovery to clinical applications,” International Immunology, vol. 22, no. 5, pp. 347–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. F. Djoba Siawaya, N. Beyers, P. van Helden, and G. Walzl, “Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis,” Clinical and Experimental Immunology, vol. 156, no. 1, pp. 69–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Hussain, A. Kaleem, F. Shahid et al., “Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population,” Journal of Immunological Methods, vol. 264, no. 1-2, pp. 95–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Fraticelli, M. Sironi, G. Bianchi et al., “Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses,” The Journal of Clinical Investigation, vol. 107, no. 9, pp. 1173–1181, 2001. View at Google Scholar · View at Scopus
  29. T. Lehner, Y. Wang, T. Whittall, and T. Seidl, “Innate immunity and HIV-1 infection,” Advances in Dental Research, vol. 23, no. 1, pp. 19–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Maurer and E. von Stebut, “Macrophage inflammatory protein-1,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 10, pp. 1882–1886, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. N. N. Chegou, G. F. Black, M. Kidd, P. D. van Helden, and G. Walzl, “Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report,” BMC Pulmonary Medicine, vol. 9, article 21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. L. Kellar, J. Gehrke, S. E. Weis et al., “Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens,” PLoS ONE, vol. 6, no. 11, Article ID e26545, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. N. N. Chegou, A. K. Detjen, L. Thiart et al., “Utility of host markers detected in quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting,” PLoS ONE, vol. 8, Article ID e64226, 2013. View at Google Scholar
  34. E. Gruys, M. J. M. Toussaint, T. A. Niewold, and S. J. Koopmans, “Acute phase reaction and acute phase proteins,” Journal of Zhejiang University, vol. 6, no. 11, pp. 1045–1056, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. K. Shaikh, J. A. Samo, B. R. Devrajani, S. Z. A. Shah, S. Shaikh, and I. Shaikh, “C-reactive protein in patients with pulmonary tuberculosis,” World Applied Sciences Journal, vol. 17, no. 2, pp. 140–144, 2012. View at Google Scholar · View at Scopus
  36. D. Wilson, M. Badri, and G. Maartens, “Performance of serum c-reactive protein as a screening test for smear-negative tuberculosis in an ambulatory high HIV prevalence population,” PLoS ONE, vol. 6, no. 1, Article ID e15248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Haghighi and J. Y. Doust, “C-reactive protein in pulmonary tuberculosis,” Diseases of the Chest, vol. 50, no. 6, pp. 624–626, 1966. View at Google Scholar · View at Scopus
  38. S. Rao and V. Bernhardt, “Serum C-reactive protein in pulmonary tuberculosis: correlation with bacteriological load and extent of disease,” Infectious Diseases in Clinical Practice, vol. 17, no. 5, pp. 314–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. G. Raynes and E. H. Cooper, “Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease,” Journal of Clinical Pathology, vol. 36, no. 7, pp. 798–803, 1983. View at Google Scholar · View at Scopus
  40. N. Eriksen, “The serum amyloid protein A lipoprotein family,” in Acute Phase Proteins: Molecular Biology Biochemistry and Clinical Applications, A. Mackewicz, I. Kushner, and H. Boumann, Eds., pp. 93–106, CRC Press, Boca Raton, Fla, USA, 1993. View at Google Scholar
  41. P. P. Singh and S. Kaur, “Serum amyloid P-component in murine tuberculosis: induction kinetics and intramacrophage Mycobacterium tuberculosis growth inhibition in vitro,” Microbes and Infection, vol. 8, no. 2, pp. 541–551, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Kagami, Y. Hiramatsu, S. Hishida et al., “Salivary growth factors in health and disease,” Advances in Dental Research, vol. 14, pp. 99–102, 2000. View at Google Scholar · View at Scopus
  43. S. Ergun, Ş. C. Troşala, S. Warnakulasuriya et al., “Evaluation of oxidative stress and antioxidant profile in patients with oral lichen planus,” Journal of Oral Pathology and Medicine, vol. 40, no. 4, pp. 286–293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Kaufman and I. B. Lamster, “The diagnostic applications of saliva—a review,” Critical Reviews in Oral Biology and Medicine, vol. 13, no. 2, pp. 197–212, 2002. View at Google Scholar · View at Scopus
  45. B. M. Branson, “FDA approves OraQuick for use in saliva. On March 25, the FDA approved the first rapid test for HIV in oral fluids,” AIDS Clinical Care, vol. 16, no. 5, p. 39, 2004. View at Google Scholar · View at Scopus